Conflicts of interest in medical technology markets: Evidence from orthopedic surgery

Health Economics (United Kingdom)

Volumn 25, Issue 6, 2016, Pages 723-739

  Smieliauskas, Fabrice ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

financial conflicts of interest; medical devices; orthopedic surgery; physician agency; physician industry relationships

Indexed keywords

ARTICLE; BIOMEDICINE; CONFLICT OF INTEREST; COST CONTROL; FINANCIAL MANAGEMENT; GOVERNMENT; HOSPITAL DISCHARGE; HUMAN; JOINT PROSTHESIS; MEDICAL DEVICE; MEDICAL PRACTICE; MEDICAL TECHNOLOGY; ORTHOPEDIC SURGEON; ORTHOPEDIC SURGERY; PHYSICIAN ATTITUDE; PHYSICIAN INCOME; POLICY; PRIORITY JOURNAL; PRODUCTIVITY; PROSPECTIVE PAYMENT; ECONOMICS; HEALTH CARE COST; INDUSTRY; PATIENT REFERRAL; PROSTHESES AND ORTHOSES; REPLACEMENT ARTHROPLASTY; SURGEON;

ARTHROPLASTY, REPLACEMENT; CONFLICT OF INTEREST; HEALTH CARE SECTOR; HUMANS; INDUSTRY; ORTHOPEDIC PROCEDURES; PROSTHESES AND IMPLANTS; REFERRAL AND CONSULTATION; SURGEONS;

EID: 84926684501     PISSN: 10579230     EISSN: 10991050     Source Type: Journal    
DOI: 10.1002/hec.3177     Document Type: Article

References (33)

1. Abadie A,. 2008. Difference-in-difference estimators. In The New Palgrave Dictionary of Economics, Durlauf SN, Blume LE, (eds.)(2nd edn), Nature Publishing Group: Basingstoke; 490-92.
2. American Association of Medical Colleges. 2008. The scientific basis of influence and reciprocity: a symposium. Washington D.C. https://members.aamc.org/eweb/DynamicPage.aspx?Action=Add&ObjectKeyFrom=1A83491A-9853-4C87-86A4-F7D95601C2E2&WebCode=PubDetailAdd&DoNotSave=yes&ParentObject=CentralizedOrderEntry&ParentDataObject=Invoice%20Detail&ivd-formkey=69202792-63d7-4ba2-bf4e-a0da41270555&ivd-prc-prd-key=34CCB27D-4F8B-4F8D-8642-47AE48D6E2B4.
3. Bozic KJ, Ong K, Lau E, et al., 2010a. Risk of complication and revision total hip arthroplasty among Medicare patients with different bearing surfaces. Clinical Orthopaedics and Related Research 468 (9): 2357-62. DOI: 10.1007/s11999-010-1262-3.
4. Bozic KJ, Pui CM, Ludeman MJ, Vail TP, Silverstein MD,. 2010b. Do the potential benefits of metal-on-metal hip resurfacing justify the increased cost and risk of complications? Clinical Orthopaedics and Related Research 468 (9): 2301-12. DOI: 10.1007/s11999-010-1301-0.
5. Cameron AC, Miller DL,. 2010. Robust inference with clustered data. In Handbook of Empirical Economics and Finance, Ullah A, Giles DEA, (eds.), Chapman & Hall/CRC: Boca Raton, FL.
6. Cassak D,. 2007. The settlement in the orthopedics investigations puts the issue to bed-or does it? In Vivo: The Business & Medicine Report, November, 58-62.
7. Cassak D,. 2010. Finbury's last stand. In Vivo: The Business & Medicine Report, February, 30-41.
8. Chatterji AK, Fabrizio KR, Mitchell W, Schulman KA,. 2008. Physician-industry cooperation in the medical device industry. Health Affairs 27 (6): 1532-43. DOI: 10.1377/hlthaff.27.6.1532.
9. Chen P-Y, Hitt LM,. 2002. Measuring switching costs and the determinants of customer retention in Internet-enabled businesses: a study of the online brokerage industry. Information Systems Research 13 (3): 255-74.
10. Chren M-M, Landefeld CS,. 1994. Physicians' behavior and their interactions with drug companies. JAMA, the Journal of the American Medical Association 271 (9): 684-89.
11. Centers for Medicare & Medicaid Services. 2014. Open payments. October 1. http://cms.gov/openpayments/.
12. Cockburn IM, Henderson RM,. 1998. Absorptive capacity, coauthoring behavior, and the organization of research in drug discovery. The Journal of Industrial Economics 46 (2): 157-82. DOI: 10.1111/1467-6451.00067.
13. Della Valle CJ, Nunley RM, Raterman SJ, Barrack RL,. 2008. Initial American experience with hip resurfacing following FDA approval. Clinical Orthopaedics and Related Research 467 (1): 72-78. DOI: 10.1007/s11999-008-0563-2.
14. Epstein RA,. 2010. How Conflict-of-Interest Regulations Endanger Medical Progress and Cures, Project FDA. Manhattan Institute: New York, NY.
15. Farrell J, Klemperer P,. 2007. Coordination and lock-in: competition with switching costs and network effects. In Handbook of Industrial Organization, Armstrong M, Porter R, (eds), Elsevier: UK; 3: 1967-2072.
16. Foray D, Lissoni F,. 2010. University research and public-private interaction. In Handbook of the Economics of Innovation, Hall BH, Rosenberg N, (eds), Elsevier: UK; 1: 275-314.
17. Hilzenrath DS,. 2009. Medical sales reps work alongside doctors, even in operating rooms. The Washington Post, December 27, sec. Business. http://www.washingtonpost.com/wp-dyn/content/article/2009/12/24/AR2009122403368.html.
18. Hockenberry JM, Weigel P, Auerbach A, Cram P,. 2011. Financial payments by orthopedic device makers to orthopedic surgeons. Archives of Internal Medicine 171 (19): 1759-65. DOI: 10.1001/archinternmed.2011.454.
19. Ho V,. 2002. Learning and the evolution of medical technologies: the diffusion of coronary angioplasty. Journal of Health Economics 21 (5): 873-85.
20. IOM (Institute of Medicine). 2009. Conflict of Interest in Medical Research, Education, and Practice, The National Academies Press: Washington D.C.
21. Lipes E,. 2008. Prepared testimony at senate committee on aging hearing. Surgeons for sale: conflicts and consultant payments in the medical device industry. Washington, D.C. http://www.aging.senate.gov/imo/media/doc/2272008.pdf.
22. Loftus P,. 2014. Doctors net billions from drug firms. Wall Street Journal, October 1: B.1. http://online.wsj.com/articles/u-s-agency-reveals-drug-makers-payments-to-doctors-1412100323.
23. Lurie N, Rich EC, Simpson DE, Meyer J, Schiedermayer DL, Goodman JL, McKinney WP,. 1990. Pharmaceutical representatives in Academic Medical Centers. Journal of General Internal Medicine 5 (3): 240-43.
24. McDermott K,. 2010. Presentation at American Academy of Orthopaedic Surgeons' annual meeting, symposium on the orthopaedic surgeon and industry relationships: evolution or revolution? presented at the American Academy of Orthopaedic Surgeons' Annual Meeting, Las Vegas, NV, March 13.
25. Mendenhall S,. 2009a. 2009 hip and knee implant review. Orthopedic Network News 20 (3): 13.
26. Mendenhall S,. 2009b. Personal communication.
27. Orlowski JP, Wateska L,. 1992. The effects of pharmaceutical firm enticements on physician prescribing patterns. Chest 102 (July): 270-73. DOI: 10.1378/chest.102.1.270.
28. Salemi T,. 2012. Smaller players see opportunity in large joints. In Vivo: The Business & Medicine Report, April.
29. Shaw J, Slemrod J, Whiting J,. 2010. Administration and compliance. In Dimensions of Tax Design: The Mirrlees Review, Adam S, et al (eds.), Oxford University Press: New York; 1100-1162.
30. Stephan PE,. 2010. The economics of science. In Handbook of the Economics of Innovation, Hall BH, Rosenberg N, (eds), Elsevier: UK; 1: 218-66.
31. Stuart M,. 2013. MedPassage's new sales model for medical devices lowers costs. Start-Up, July.
32. US Attorney's Office-New Jersey. 2009. Monitoring and deferred prosecution agreements terminated with companies in hip and knee replacement industry. http://www.justice.gov/usao/nj/Press/files/pdffiles/2009/hips0330%20rel.pdf.
33. Zucker LG, Darby MR, Armstrong J,. 1998. Geographically localized knowledge: spillovers or markets? Economic Inquiry 36 (1): 65-86. DOI: 10.1111/j.1465-7295.1998.tb01696.x.